Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of QVA149 in COPD Patients

ClinicalTrials.gov ID: NCT02487446

Public ClinicalTrials.gov record NCT02487446. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Double-blind, Double-dummy, Active Controlled, 2-period Cross-over Study to Assess the Efficacy, Safety and Tolerability of Indacaterol Maleate/Glycopyrronium Bromide Compared to Umeclidinium Bromide/Vilanterol in COPD Patients With Moderate to Severe Airflow Limitation

Study identification

NCT ID
NCT02487446
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
357 participants

Conditions and interventions

Interventions

  • QVA149 Drug
  • Umeclidinium/vilanterol Drug
  • Placebo (umeclidinium/vilanterol) Drug
  • Placebo (QVA149) Drug

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 27, 2015
Primary completion
Sep 11, 2016
Completion
Sep 11, 2016
Last update posted
Dec 25, 2017

2015 – 2016

United States locations

U.S. sites
58
U.S. states
21
U.S. cities
55
Facility City State ZIP Site status
Novartis Investigative Site Andalusia Alabama 36305
Novartis Investigative Site Anniston Alabama 36207-5710
Novartis Investigative Site Jasper Alabama 35501
Novartis Investigative Site Multiple Locations Alabama
Novartis Investigative Site Multiple Locations Arizona
Novartis Investigative Site Tempe Arizona 85283
Novartis Investigative Site Tucson Arizona 85723
Novartis Investigative Site Fayetteville Arkansas 72703
Novartis Investigative Site Huntington Beach California 92647
Novartis Investigative Site Rancho Mirage California 92270
Novartis Investigative Site Colorado Springs Colorado 80907
Novartis Investigative Site Altamonte Springs Florida 32701
Novartis Investigative Site DeLand Florida 32720
Novartis Investigative Site Fort Lauderdale Florida 33316-192
Novartis Investigative Site Kissimmee Florida 34741
Novartis Investigative Site Miami Florida 33172
Novartis Investigative Site Pensacola Florida 32503
Novartis Investigative Site Pensacola Florida 32504
Novartis Investigative Site Port Orange Florida 32127
Novartis Investigative Site Conyers Georgia 30094
Novartis Investigative Site Duluth Georgia 30096
Novartis Investigative Site Meridian Idaho 83642
Novartis Investigative Site New Orleans Louisiana 70119
Novartis Investigative Site Slidell Louisiana 70458
Novartis Investigative Site Sunset Louisiana 70584
Novartis Investigative Site Columbia Maryland 21044
Novartis Investigative Site Edina Minnesota 55435
Novartis Investigative Site Fridley Minnesota 55432
Novartis Investigative Site Minneapolis Minnesota 55402
Novartis Investigative Site Minneapolis Minnesota 55407
Novartis Investigative Site Plymouth Minnesota 55441
Novartis Investigative Site Henderson Nevada 89014
Novartis Investigative Site New York New York 10016
Novartis Investigative Site Charlotte North Carolina 28207
Novartis Investigative Site Cornelius North Carolina 28031
Novartis Investigative Site Gastonia North Carolina 28054
Novartis Investigative Site Hickory North Carolina 28602
Novartis Investigative Site High Point North Carolina 27262
Novartis Investigative Site Huntersville North Carolina 28078
Novartis Investigative Site Winston-Salem North Carolina 27103
Novartis Investigative Site Cincinnati Ohio 45242
Novartis Investigative Site Columbus Ohio 43213
Novartis Investigative Site Columbus Ohio 43215
Novartis Investigative Site Dublin Ohio 43016
Novartis Investigative Site Marion Ohio 43302
Novartis Investigative Site Medford Oregon 97504
Novartis Investigative Site Portland Oregon 97213
Novartis Investigative Site Philadelphia Pennsylvania 19142
Novartis Investigative Site Tipton Pennsylvania 16684
Novartis Investigative Site Carrollton Texas 75010
Novartis Investigative Site Channelview Texas 77530
Novartis Investigative Site Fort Worth Texas 76109
Novartis Investigative Site Lampasas Texas 76550
Novartis Investigative Site McKinney Texas 75069
Novartis Investigative Site New Braunfels Texas 78130
Novartis Investigative Site Salt Lake City Utah 84102
Novartis Investigative Site Newport News Virginia 23606
Novartis Investigative Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02487446, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 25, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02487446 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →